Assessment of YME1L and mitofusin2 as a possible diagnostic and/or therapeutic target in hepatocellular carcinoma

Simple item page
dc.contributor.authorMohie Abdel-Hamid, Nabilen_US
dc.contributor.authorAbass, Shimaa Alien_US
dc.contributor.authorEldomany, Ramadanen_US
dc.contributor.authorzakaria, sherinen_US
dc.date.accessioned2023-08-09T06:03:10Z
dc.date.available2023-08-09T06:03:10Z
dc.date.issued2023-01
dc.description.abstractMitochondrial dynamics are a contraversal issue in hepatocellular carcinoma. The present study tries to illustrate the role of mitochondrial dynamics proteins (mitofusin-2 (Mfn2) and YME1L) in hepatocarcinogenesis. Five groups were used: the control group and three HCC groups (after 8, 16, and 24 weeks from DENA induction). The last group was treated with Sorafenib (SP) (10 mg/kg), via oral gavage for 4 weeks after cancer induction. This study revealed that Mfn-2 was downregulated and YME1l was overexpressed in different HCC groups. This dysregulation of mitochondrial dynamics proteins was associated with high hepatic levels of cyclin D1, MMP-9, and MDA and overexpression of ki67 as well as decreasing the hepatic expression of tissue inhibitor of matrix metalloproteinase-3 (Timp-3) and Bax. To confirm the possible role of Mfn2 and YME1L in HCC, we assessed the effect of sorafenib on these parameters and its related HCC characteristics. Sorafenib corrected the level of Mfn2 and YME1L and decreased tumor cell proliferation as well. We also elucidated that mitochondrial dynamics proteins (Mfn2 and YME1L) could be a good therapeutic target for HCC.en_US
dc.identifier.affiliationsBiochemistry Departmenten_US
dc.identifier.affiliationsDepartment of Microbiology and Immunologyen_US
dc.identifier.affiliationsDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh-33516, Egypten_US
dc.identifier.citationMohie Abdel-Hamid Nabil, Abass Shimaa Ali, Eldomany Ramadan, zakaria sherin. Assessment of YME1L and mitofusin2 as a possible diagnostic and/or therapeutic target in hepatocellular carcinoma. Indian Journal of Biochemistry & Biophysics. 2023 Jan; 60(1): 43-54en_US
dc.identifier.issn0019-5189
dc.identifier.issn0975-1009
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/221646
dc.languageenen_US
dc.publisherCSIR-NIScPRen_US
dc.relation.issuenumber1en_US
dc.relation.volume60en_US
dc.source.urihttps://doi.org/10.56042/ijbb.v60i1.62503en_US
dc.subjectHCC biomarkeren_US
dc.subjectMatrix metalloproteinaseen_US
dc.subjectMitochondrial dynamicsen_US
dc.subjectMitochondrial fusionen_US
dc.subjectTIMP-3en_US
dc.titleAssessment of YME1L and mitofusin2 as a possible diagnostic and/or therapeutic target in hepatocellular carcinomaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJBB2023v60n1p43.pdf
Size:
670.35 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Biochemistry & Biophysics